National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

R-flurbiprofen
An orally active synthetic enantiomer of flurbiprofen. R-flurbiprofen activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Flurizan
Code names:E-7869
MPC-7869
Chemical structure name:(R)-2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid



Previous:quinidine, quinine, Quixin, Qvar, R(+)XK469
Next:racemic XK469, RadiaPlex Rx Gel, Raf kinase inhibitor XL281, raloxifene, raltitrexed

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov